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Open access under the ElsObjectives: Determination of the SET protein levels in head and neck squamous cell carcinoma (HNSCC)
tissue samples and the SET role in cell survival and response to oxidative stress in HNSCC cell lineages.
Materials and Methods: SET protein was analyzed in 372 HNSCC tissue samples by immunohistochemistry
using tissue microarray and HNSCC cell lineages. Oxidative stress was induced with the pro-oxidant tert-
butylhydroperoxide (50 and 250 lM) in the HNSCC HN13 cell lineage either with (siSET) or without
(siNC) SET knockdown. Cell viability was evaluated by trypan blue exclusion and annexin V/propidium
iodide assays. It was assessed caspase-3 and -9, PARP-1, DNA fragmentation, NM23-H1, SET, Akt and
phosphorylated Akt (p-Akt) status. Acidic vesicular organelles (AVOs) were assessed by the acridine
orange assay. Glutathione levels and transcripts of antioxidant genes were assayed by ﬂuorometry and
real time PCR, respectively.
Results: SET levels were up-regulated in 97% tumor tissue samples and in HNSCC cell lineages. SiSET in
HN13 cells (i) promoted cell death but did not induced caspases, PARP-1 cleavage or DNA fragmentation,
and (ii) decreased resistance to death induced by oxidative stress, indicating SET involvement through
caspase-independent mechanism. The red ﬂuorescence induced by siSET in HN13 cells in the acridine
orange assay suggests SET-dependent prevention of AVOs acidiﬁcation. NM23-H1 protein was restricted
to the cytoplasm of siSET/siNC HN13 cells under oxidative stress, in association with decrease of cleaved
SET levels. In the presence of oxidative stress, siNC HN13 cells showed lower GSH antioxidant defense
(GSH/GSSG ratio) but higher expression of the antioxidant genes PRDX6, SOD2 and TXN compared to siSET
HN13 cells. Still under oxidative stress, p-Akt levels were increased in siNC HN13 cells but not in siSET
HN13, indicating its involvement in HN13 cell survival. Similar results for the main SET effects were
observed in HN12 and CAL 27 cell lineages, except that HN13 cells were more resistant to death.
Conclusion: SET is potential (i) marker for HNSCC associated with cancer cell resistance and (ii) new tar-
get in cancer therapy.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.4,5Introduction
Cancer cells have the ability to escape the induction of death1
and to protect themselves from antineoplastic therapies;2 in
patients with head and neck squamous cell carcinoma (HNSCC)
this is reﬂected in high rate of recurrence.3 Several changes in
the amounts and/or phosphorylation status of proteins in variouso).
evier OA license.signaling pathways have been identiﬁed in HNSCC. Akt phos-
phorylation, which is one endpoint of the phosphatidylinositol 3-
kinase (PI3K) signaling pathway,6 is an important event in the
pathogenesis of HNSCC;7,8 it has been detected in nearly 50% of
pre-neoplastic tongue lesions and predicts poor clinical outcome.9
A recent proteomic analysis of HNSCC samples identiﬁed the
SET protein (I2PP2A or TAF1b) as accumulated in oral tumors.10
SET, a strong and selective PP2A inhibitor,11 which was ﬁrst
described in acute undifferentiated leukemia,12 has multiple pro-
posed functions such as NM23-H1 inhibition,13 Rac-1 interaction
A.M. Leopoldino et al. / Oral Oncology 48 (2012) 1106–1113 1107and migration,14 chromatin remodeling15 and Akt activation.16,17
Its fragmentation was observed in Alzheimer disease brain extract
from hippocampus; in neurons, SET/I2PP2A co-localized in cyto-
plasm with PP2A.18 Recently, SET was proposed as a potential ther-
apeutic target in breast cancer cells because its inhibition led
NM23-H1, a DNAse, to move into to nucleus, activated PP2A and
abolished Rac-1 interaction.19
The involvement in the cell response to oxidative stress was
recently proposed as a new function for SET protein in HEK293T,
a transformed human embryonic kidney cell line.16 In cancer cells,
oxidative stress and Akt phosphorylation have been associatedwith
energetic and redox balance alterations, which may contribute
signiﬁcantly for tumor development and progression.1,20–23 In this
regard, adaptation to the unbalance redox and antioxidant
defense, as well as Akt signaling, may be implicated in the resis-
tance of cancer cells to death.22,24–26 Akt/mTOR inhibition, which
has been proposed as a complement in the cancer therapy with cis-
platin and radiation, sensitizes cells to death by autophagy in asso-
ciationwith the formation of acidic vesicular organelles (AVOs).27,28
In this work we investigated the SET protein in HNSCC samples
by immunohistochemistry using tissue microarray, and in a panel
of cell lineages, and also addressed the role of SET in HNSCC cell sur-
vival and response to oxidative stress. The rationales for this study
were: (i) SET accumulates in HNSCC, as suggested by proteomic
analysis,10 (ii) SET inhibits PP2A29 and NM23-H1,30 (iii) phosphory-
lated Akt (p-Akt) prevents cell death,31 (iv) PP2A dephosphorylates
Akt,32 (v) oxidative stress can induce either cell death or sur-
vival,16,20,33 and (vi) AVOs/autophagy has been associated with
resistance to radiation34 or oxidative stress-induced death35 in
cancer cells. Studies were conducted in the HNSCC cell lineage
HN13, as well as HN12 and CAL 27, with SET knockdown; oxidative
stress was induced with the pro-oxidant tert-butylhydroperoxide
(t-BHP). The results conﬁrm that SET accumulates in HNSCC and
provide evidence that SET promotes HNSCC cell survival. Potential
mechanisms involved are presented.Materials and methods
Tissue microarray and immunohistochemistry
Samples and tissue microarrays (TMAs-NIH) from 372 cases of
HNSCC, dysplastic and normal squamous epithelium (as control)
tissues were obtained from the National Institute of Dental and
Craniofacial Research (NIDCR) NIH Oral Cancer Tissue Array Initia-
tive (Bethesda, MD, USA).5 Immunohistochemistry (IHC) was per-
formed as previously described.36 Two experienced pathologists
assessed the immunostaining results. Tumors were classiﬁed into
ﬁve different grades according to the number of positive cells per
100 tumor cells: 0 (0–10% positive cells), 1 (10–25% positive cells),
2 (25–50% positive cells), 3 (50–75% positive cells), and 4 (75–100%
positive cells).Cell lines and culture conditions
Human HNSCC cell lineages (HN4, HN6, HN8, HN12, HN13,
HN17, HN19, HN22, HN26, HN30, and HN31)37 and two immortal-
ized oral keratinocyte (NOK-SI and IHOK),38 as well as CAL 27 cell
lineage (ATCC), were cultured in DMEM supplemented with 10%
fetal bovine serum, penicillin (100 U/ml), and streptomycin
(100 mg/ml) (SIGMA, MO, USA) at 37 C in a humidiﬁed atmo-
sphere containing 5% CO2. Oxidative stress was induced with
t-BHP (SIGMA) in the absence or presence of 10% fetal bovine ser-
um. At harvest, cells were washed with phosphate-buffered saline
(PBS) and lysed in sodium dodecyl sulfate (SDS) sample buffer sup-
plemented with protease inhibitor cocktail (SIGMA).SET knockdown
HN13 and CAL 27 cells were seeded in 6-well or 24-well plates
at 70% conﬂuence, washed twice in serum-free medium, and trans-
fected with SMARTpool oligonucleotide directed against human
SET (siSET) and scrambled siRNA as negative control (siNC)
(Dharmacon or Qiagen) using DharmaFECT (Dharmacon, CO, USA)
or HiPerFect reagent (Qiagen) according to the manufacturer’s
instructions. The optimal siRNA oligonucleotide concentrations
and time points were determined by siRNA dilution curve. After
72 h, cells were treated as indicated. For HN12 cells, transfection
was performed with the MISSION shRNA Plasmid TCR1 DNA
against human SET (shSET) (TRCN0000063717; NM_003011.
1-467s1c1) and the empty vector (shNC) (pLKO.1puro; SHC001,
SIGMA) using Polyfect reagent (Qiagen) and puromycin selection
for stable RNA interference against SET. The knockdown at the pro-
tein level was monitored by immunoblotting analysis.Annexin V/propidium iodide (PI) assay
After treatments, cells were detached and 1  105 cells were
analyzed using the FITC Annexin V Apoptosis Detection Kit I (BD
Biosciences, CA, USA). Brieﬂy, cells were washed with PBS and
incubated with FITC Annexin V/PI for 15 min at RT (25 C) in the
dark. After the reaction was complete, cells were analyzed in a
BD FACSCanto™ Flow Cytometry System (BD Biosciences) using
the BD FACSDiva 4.1.2. Software (BD Biosciences).Trypan blue exclusion assay
After treatments, cells were harvested and incubated for 3 min
in PBS with 0.4% (w/v) trypan blue (SIGMA), a diazo dye that is
excluded by viable cells.39 Cell viability was analyzed by micros-
copy using a hemocytometer.Caspases activity assays
Caspase-9 activity was determined using the Colorimetric Pro-
tease Assay Kit (Calbiochem-Behring) based on the detection of
the chromophore p-nitroanilide (pNA) released from LEHD-pNA
at 405 nm in a microplate reader (Bio-Rad). Caspase-8 activity
was determined using a ﬂuorimetric assay with Ac-IETD-AMC
through the detection of the ﬂuorophore 7-amino-4-methyl cou-
marin (AMC) with a 400/505 nm excitation/emission wavelength
pair in an F-4500 Hitachi ﬂuorescence spectrophotometer.Immunoblotting
Cultured cells were harvested and sonicated, and the protein
concentrations of the lysates were determined using a DC protein
assay (Bio-Rad). Aliquots of total protein (30–50 lg) from each
whole-cell lysate were separated by gel electrophoresis. Immuno-
blotting was performed using primary antibodies anti-poly (ADP
ribose) polymerase 1 (PARP) (#MAB3290, Millipore), anti-cas-
pase-3 (clone 8G10; #9665), anti-Akt (cat#9272), anti-PP2A C
subunit (#2038), anti-p-AktSer473 (clone 736E11; #3787), anti-
ﬁbrilarin (clone C13C3; #2639) and anti-p-AktThr308 (clone
C31E5E; #2965) (Cell Signaling Technology). Primary antibodies
anti-SET (E-15; #sc5655), anti-NM23-H1 (clone C20; #sc343),
anti-b-actin (clone C4; #sc47778) and anti-a-tubulin, as well as
anti-rabbit, anti-mouse and anti-goat secondary antibodies conju-
gated with horseradish peroxidase (Santa Cruz Biotechnology),
were also used. Bound antibodies were detected with ECL™
Systems (GE Health Care).
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Alkaline agarose gel electrophoresis can be used to analyze the
fragmentation of double-stranded DNA: DNA is denatured, main-
tained in its single-stranded form, and migrates according to its
size. DNA was extracted using a standard protocol,40 and alkaline
agarose gel electrophoresis was conducted as previously
described,41 with 20 lg of total DNA separated on alkaline agarose
gels and stained with SYBR Gold (Invitrogen).Acridine orange assay for assessment of AVOs acidiﬁcation
In cytoplasm and nucleus acridine orange ﬂuoresces bright
green and dim red whereas in AVOs and subcellular compartments
it ﬂuoresces bright red proportionally to acidity or volume.34 Cells
were stained with acridine orange as previously described34 and
red ﬂuorescence intensity was visualized by ﬂuorescence micros-
copy using Zeiss Axiovert 40 CFL Microscope/Zeiss AxioVision
4.8.2 software (Zeiss). Experimental controls for acridine orange-
accumulating AVOs: (i) cells were incubated with acridine orange
(1 lg/mL DMEM phenol red-free) for 15 min, 20 mM NH4Cl was
added and bright red was lost,42,43 and (ii) cells were incubated
with 10 lM pP242 (SIGMA) for 2 h, a mTOR inhibitor which
induces AVOs formation, and bright red increased.44Reduced (GSH) and oxidized (GSSG) glutathione assay
GSH and GSSG were determined ﬂuorometrically in cell suspen-
sions (2  105) with o-phthalaldehyde.16Quantitative real-time polymerase chain reaction (qPCR)
RNA was isolated from treated cells with Trizol reagent (Invitro-
gen). The isolated RNA was used as a template for cDNA synthesis
with SuperScript II reverse transcriptase (Invitrogen). Quantitative
real-time PCR (qPCR) for the human genes PRDX2, PRDX6, SOD2,
TXN and GAPDH was performed as previously reported.16Figure 1 SET is accumulated in HNSCC tissues and cell lines. (A) Graphic representation o
scores of 2, 3 or 4 and exhibited mainly nuclear SET staining. (B) SET staining in represen
squamous carcinomas (CA), showing different SET immunoreactivity and distribution
staining in the lower half of the squamous epithelium in a mild dysplasia of the oral m
staining in another CA. Samples were subjected to immunohistochemistry with antibody
with Harris hematoxylin. (C) SET protein levels in HN13 cells compared to oral keratinocy
lines, including HN13.Statistical analysis
Statistical analyses were performed using the GraphPad Prism
5.0 software (San Diego, CA, USA). Fisher’s Exact, Chi-square, t-test,
and one-way or two-way ANOVA followed by Bonferroni or
Dunnett’s post hoc tests. Results were expressed as the mean ± -
SEM. P values <0.05 were considered statistically signiﬁcant.Results
SET accumulates in HNSCC
To assess the potential involvement of SET in HNSCC, we ana-
lyzed the SET levels using TMAs of HNSCC samples by IHC. Approx-
imately 97% of the tumor samples (n = 372) expressed high levels
of SET (Fig. 1A), mainly in the nucleus (Fig. 1A, insert). Remarkably,
SET was absent in normal epithelium and initially up-regulated in
dysplastic epithelium (Fig. 1B), which is typical of pre-malignant
lesions. We also analyzed a larger set of HNSCC tissue samples.
SET was always present in the nucleus (Fig. 1B – CA), and it was
accompanied by cytoplasmic staining (Fig. 1B – CA, bottom right)
in 10% of HNSCC TMAs. These features were consistent with the
higher levels of SET observed in the HNSCC HN13 cell lineage com-
pared to oral keratinocytes (NOK-SI and IHOK) (Fig. 1C). Other
HNSCC cell lineages also accumulated SET protein (Fig. 1D), whose
cleavage (28, 25 and 20 kDa)18,45 was visualized. HN13 cells
showed stronger bands and for this reason they were chosen for
the subsequent studies. The fragment of 20 kDa was previously
proposed as involved in PP2A inhibition/tau hyperphosphorylation
and associated with cytoplasmic location of SET in Alzheimer
disease cases.45SET accumulation contributes to survival of HNSCC cells under
oxidative stress
One of the hallmarks of cancer cells is their acquired ability to
prevent cell death, promoting metabolic adaptation and survival
of tumor under adverse conditions.1 SiSET promoted HN13 cellf SET expression in all positive cases (n = 372); 97% of the positive cases had staining
tative histological samples of normal oral epithelium, oral dysplasias, and two oral
patterns: negative staining for SET in normal epithelium, predominantly nuclear
ucosa, extensive nuclear staining in a CA, and extensive nuclear and cytoplasmic
against SET, staining with diaminobenzidine as a chromogen, and counterstaining
tes (NOK-SI and IHOK). (D) SET protein levels in a panel of representative HNSCC cell
Figure 2 Characterization of death of siSET HN13 cells compared to siNC HN13. Cells were incubated in DMEM at 37 C in the absence or presence of t-BHP at the
concentrations indicated, for 2 h, except in A and D, for 1 h. (A) Cells stained with FITC-conjugated Annexin V and PI, assessed by ﬂow cytometry. (B) Trypan blue exclusion
assay (viability). (C) Caspase-3 cleavage, assessed by immunoblotting; pP242 and actinomycin D (AcD): positive controls. (D) Caspase-8 and caspase-9 activities, assessed
with labeled substrates. (E) PARP cleavage, assessed by immunoblotting; pP242 and AcD: positive controls, and chloroquine (CQ): autophagy inhibitor. (F) DNA fragmentation
analyzed by alkaline agarose gel electrophoresis stained with SYBR GOLD; AcD: positive control. A–F: At least three independent experiments were performed (A, B and D, in
triplicate), as described in Materials and methods. In A and B, the P values shown indicate statistically signiﬁcant differences: P < 0.05, P < 0.01 and P < 0.001. In D, no
between-group differences were statistically signiﬁcant (P > 0.05).
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V-positive cells co-stainedwith PI (Fig. 2A). Oxidative stress (50 and
250 lM t-BHP, 2 h incubation) only affected viability of siSET HN13
cells, as detected by trypan blue exclusion assay (Fig. 2B), indicating
that HN13 cells are more resistant to oxidative stress-induced cell
death and that SET may play a role in this characteristic. Similar
analysis for HN12 and CAL 27 cells (Fig. S1-A) indicated lower resis-
tance of these cells to oxidative stress-induced death in relation to
HN13 cells. The assays of caspase-3 cleavage (Fig. 2C) and caspase-9
and -8 activities (Fig. 2D) indicated that HN13 cell death promoted
by siSET and exposure to t-BHP was caspase-independent. Accord-
ingly, PARP cleavage and DNA fragmentation analyses (2 h exposi-
tion to t-BHP), indicated a non-apoptotic siSET HN13 cell death
(Fig. 2E and F, respectively).
SET accumulation inﬂuences GSH levels in HN13 cells under oxidative
stress
Tumor cells are at least in part selected under oxidative stress as
a metabolic adaptation for survival. Glutathione (GSH, reduced
form) is a major cellular antioxidant that provides reducing equiv-
alents for the glutathione peroxidase-catalyzed reduction of
hydroperoxides, yielding oxidized glutathione (GSSG). The redox
imbalance in favor of GSSG and/or reactive oxygen species accu-
mulation has been implicated in t-BHP-induced cell death, and it
is known to involve the mitochondria.46 While siSET HN13 cellspresented a decreased GSH/GSSG ratio after exposure to 250 lM
t-BHP, siNC HN13 cells did not undergo a signiﬁcant change
in GSH/GSSG ratio (Fig. 3A). This result suggests that one of
consequences of SET accumulation in HN13 cells is decrease of
GSH antioxidant defense, consistent with the expected increase
in metabolism and reactive oxygen species generation in cancer
cells, including in response to Akt activation.7,20,23SET accumulation regulates expression of antioxidant genes in HN13
cells under oxidative stress
Alterations in the antioxidant proteins peroxiredoxin (PRDX),
superoxide dismutase 2 (SOD2) and thioredoxin (TXN) are impor-
tant hallmarks of cancer cells.25,47–51 Therefore, we analyzed the
expression of the respective genes in HN13 cells (Fig. 3B). SiSET
promoted the down-regulation of PRDX6, SOD2 and TXN mRNAs.
In the presence of 50 lM t-BHP, siNC HN13 cells, but not siSET
HN13, exhibited an up-regulation of PRDX6, SOD2 and TXN and a
down-regulation of PRDX2. In the presence of 250 lM t-BHP,
PRDX2, PRDX6 and SOD2 were down-regulated in both siNC and
siSET HN13 cells; TXN up-regulation was maintained in siNC
HN13 cells and down-regulated in siSET HN13. These results
indicate that at relatively low t-BHP concentration the cell re-
sponse involves PRDX6, SOD2 and TXN expression, while at rela-
tively high t-BHP concentration the cell response involves TXN
Figure 3 Antioxidant defense of siSET HN13 cells compared to siNC HN13. Cells
were incubated for 1 h in DMEM at 37 C in the absence or presence of t-BHP at the
concentrations indicated. (A) GSH/GSSG ratio, determined as described in Materials
and methods. The P value shown indicates statistically signiﬁcant difference:
P < 0.05. (B) Relative amounts of mRNA for genes encoding antioxidant proteins. At
least three independent experiments were performed in triplicate.
Figure 4 SET accumulation, phosphorylated Akt (p-Akt) and SET/NM23-H1 location
in siSET HN13 cells compared to siNC HN13. (A) HN13 cells (siNC) were treated
with okadaic acid to evaluate the up-regulation of Akt phosphorylation associated
with PP2A inhibition. The antibodies used were anti-SET, anti-Akt, anti-p-AktThr308
and anti-a-tubulin, visualized by chemiluminescence. (B) HN13 cells were analyzed
by immunoblotting using anti-SET and anti-b-actin antibodies. (C) HN13 cells were
incubated with t-BHP (50 lM) for 0–120 min and analyzed by immunoblotting with
antibodies anti-p-AktSer473, anti-Akt and anti-b-actin. (D) A representative histo-
gram of the p-Akt/Akt ratios in C (three independent experiments were used). (E)
Immunoblotting, representative of two independent experiments, using anti-SET,
anti-NM23-H1, anti-ﬁbrilarin and anti-b-actin antibodies in cytoplasmic (C)
and nuclear (N) fractions of HN13 cells incubated in the presence or absence of
t-BHP for 2 h.
1110 A.M. Leopoldino et al. / Oral Oncology 48 (2012) 1106–1113gene expression only. Furthermore, all of the tested genes exhib-
ited SET-dependent expression patterns.
SET accumulation sustains the levels of phosphorylated Akt in HN13
cells under oxidative stress
The SET protein inhibits PP2A, a phosphatase that dephospho-
rylates Akt (at Ser473 and Thr308).32 HN13 cells were treated with50 nM okadaic acid (0–60 min), a chemical PP2A inhibitor, to
assess the speciﬁc effects of PP2A and SET on p-AktThr308 levels. A
time-dependent increase in p-Akt upon okadaic acid treatment
was observed (Fig. 4A). The effect of SET on Akt dephosphorylation
was then assessed in HN13 cells under oxidative stress. After 48 h
of transfection to promote SET knockdown (Fig. 4B), HN13 cells
were incubated with 50 lM t-BHP for 0–120 min. At 60–120 min
of incubation these cells presented dissimilar Akt phosphorylation
patterns (Fig. 4C and D): p-AktSer473 levels were increased in siNC
HN13 cells but not in siSET HN13. These results suggest that SET
contributes to sustaining high p-Akt levels in HN13 cells in
response to oxidative stress.
Figure 5 Red ﬂuorescence (acridine orange assay) in siSET HN13 cells compared to siNC HN13, as described in Material and methods. Cells were incubated for 2 h in DMEM,
at 37 C, in the absence or presence of t-BHP. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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cells
Non-metastatic cells 1 (NME1 or NM23-H1), a multifunctional
protein which acts as a metastasis suppressor, is reduced by
NADPH-TrxR-Trx system;52 SET was reported to inhibit both its
activity and shift from cytoplasm to the nucleus.30,53 NM23-H1
protein was similarly distributed in nucleus and cytoplasm both
in siNC and siSET HN13 cells (Fig. 4E). On the other hand, in
HN12 and CAL 27 cells NM23-H1 was exclusively located in cyto-
plasm (data not shown). HN13 cells (Fig. 4E), as well as HN12 and
CAL 27 (data not shown), were also analyzed for NM23-H1 under
oxidative stress and only cytoplasmic location was observed.
Regarding the SET protein, in HN13 cells, cleaved SET was mainly
located in the cytoplasm whereas full protein was mainly located
in the nucleus (Fig. 4E); oxidative stress decreased cleaved SET
and increased full SET levels in cytoplasm. These ﬁndings indicate
that SET knockdown in HNSCC cells cannot promote NM23-H1
shift to the nucleus, differently from reported for breast cancer
cells using a synthetic peptide proposed as SET inhibitor.19 There-
fore, in HNSCC cells other mechanisms should control shuttling of
NM23-H1, whose accumulation in cytoplasm seems associated
with cell response to oxidative stress accompanied by decreased
SET cleavage.SET knockdown acidiﬁes AVOs in HNSCC cells
In the acridine orange microscopy assay the intensity of red
ﬂuorescence is proportional to AVOs acidiﬁcation, which has been
generally associated to autophagy. AVOs acidiﬁcation was higher
in siSET HN13 cells than in siCN HN13 and oxidative stress
increased this effect (Fig. 5). These ﬁndings suggest a participation
of AVOs acidiﬁcation in the SET knockdown-induced death, as well
as in the sensitization of HN13 cells to oxidative stress shown in
Fig. 2B, with a SET involvement via Akt/mTOR signaling pathway.27
Similar results were obtained for HN12 and CAL 27 cells (Fig. S1-B).
Therefore, SET knockdown may be regarded as a strategy to im-
prove HNSCC cell death in association with radiation or cisplatin,
as has been proposed for Akt/mTOR inhibitors.27,28Discussion
The SET/I2PP2A protein is an established inhibitor of PP2A,
which is responsible for the dephosphorylation of Akt. A recent
proteomic analysis identiﬁed SET as up-regulated in HNSCC,10which also exhibits deregulated PI3K-Akt pathway signaling.54,55
In this context, we conﬁrmed that SET protein accumulates in
HNSCC and showed cleaved SET present in cell lineages, suggesting
PP2A inhibition by a SET fragment, as proposed for Alzheimer dis-
ease.18,45 The Warburg effect implies that tumor cells are adapted
to oxidative stress22 such that the apoptosis cascade is regulated to
prevent cell death; Akt, which is sensitive to oxidative stress, is
probably involved in this signaling.33 Recently, it has been reported
resistance of cancer cells to radiation or cisplatin therapies in asso-
ciation with increased cell response to oxidative stress.24,34,56 In
this context, we asked whether SET accumulated in HNSCC may
contribute to cell survival and response to oxidative stress.
PARP cleavage, DNA fragmentation and caspases activation are
established apoptosis markers. SiSET in HN13 cells promoted cell
death characterized by rapid phosphatidylserine exposure (stain-
ing with annexin V, co-stained with PI) but not caspases activation,
PARP cleavage or DNA fragmentation, indicating that SET is
involved in the resistance of HN13 cells to death through cas-
pase-independent mechanism. In fact, siNC HN13 cells were more
resistant than siSET HN13 to oxidative stress (trypan blue exclu-
sion assay) and none of the apoptosis markers were signiﬁcantly
altered for siSET or oxidative stress in HN13 cells. These results
indicate a SET action in either PP2A11 or NM23-H1.13 Recent re-
ports have associated NM23-H1 with oxidative stress,52 mainly
in HNSCC,57 as well as its cytoplasmic location with SET binding.19
Moreover, it has been proposed that granzyme action in SET pro-
motes NM23-H1 translocation to into nucleus where SET is cleaved
and NM23-H1 acts as a DNAse.30 HN13 cells presented high levels
of NM23-H1 and both nuclear and cytoplasmic distribution of the
protein whereas CAL 27 and HN12 cells presented lower NM23-H1
levels and a cytoplasmic distribution; siSET in these cells did not
change this proﬁle. Accordingly, HN13 cells presented higher levels
of cleaved SET in cytoplasm. However, in all HNSCC cells under oxi-
dative stress NM23-H1 was restricted to cytoplasm, suggesting
that the protein is not working as an active nuclear DNAse30, but
rather, in agreement with previous reports,52,58 that it is involved
in cell response to oxidative stress. These ﬁndings reinforce the
association between nuclear location of NM23-H1 and resistance
to cell death in HNSCC57; they show, in addition, that under oxida-
tive stress, NM23-H1 is located exclusively in cytoplasm and SET
knockdown per se cannot promote its nuclear shift and DNAse
activity. Therefore, nuclear shuttling of NM23-H1 has a complex
control and SET cleavage and oxidative stress are involved.
High oxidative stress condition (1 mM H2O2 for 24–72 h) in
HEK293 and U87 cell lineages was reported to promote cell death
by autophagy, independent of apoptosis.35 HN13 cells exposed to
1112 A.M. Leopoldino et al. / Oral Oncology 48 (2012) 1106–1113t-BHP did not undergo a signiﬁcant change in GSH/GSSG ratio sug-
gesting that the glutathione antioxidant system had already been
exhausted in these cells, or alternatively, that they present an
up-regulated antioxidant defense. Indeed, exposition of siSET
HN13 cells to t-BHP (relative high concentration) promoted a de-
crease of GSH/GSSG ratio, as can be expected in the case of non-tu-
mor cells. PRDX6, SOD2 and TXNmRNA levels were down-regulated
in siSET HN13 cells and did not increase under low t-BHP concen-
tration, in contrast to what was observed in siNC HN13 cells. These
results suggest that while glutathione antioxidant system is
exhausted, other important cellular antioxidant systems are acti-
vated, in a SET-dependent way, in order to prevent HN13 cell
death.
Remarkably, siSET in HN13 cells per se resulted in reduced cell
viability, reinforcing the SET relevance to the survival of these
tumor cells, but siSET did not impact on cellular distribution of
NM23-H1.13,52,53 Another proposed SET function is inhibition of
the tumor suppressor PP2A, which dephosphorylates Akt at both
Thr308 and Ser473.32 Therefore, phosphorylated Akt was analyzed
and in siSET HN13 cells a loss of p-Akt was found, indicating that
it is involved in HN13 cell survival. It has been reported that under
high hydrogen peroxide levels, Akt1 phosphorylation is inhibited
and induces apoptosis.33 This evidence highlights the link between
redox status, Akt and the ability of cancer cells to escape the induc-
tion of death by either stimulating Akt phosphorylation or prevent-
ing Akt dephosphorylation. Our results indicate that SET protein is
required to sustain phosphorylated Akt under oxidative stress;
however, SET knockdown-promoted p-Akt loss and oxidative stress
were insufﬁcient to induce apoptosis in HNSCC cells. AVOs forma-
tion (or its acidiﬁcation), which has been associated with autoph-
agy, is inhibited by active Akt-mTOR.44 In this regard, the siSET
in HN13, CAL 27 and HN12 cells decreased cell viability, as well
as increased red ﬂuorescence, suggesting a SET action in cell death
signaling involving AVOs acidiﬁcation, and perhaps autophagy.
The present study reveals a new and important function for the
SET protein, at least in HNSCC, because adaptation to oxidative
stress is an early cell event in tumorigenesis1 and associated with
cancer resistance to therapy.59 It indicates that SET overexpres-
sion/accumulation in tumors may be an important step for its
development and progression. SET is, therefore, a potential marker
for HNSCC as well as a potential therapeutic target, which could, in
combination with other antitumor therapies, circumvent the resis-
tance of cancer cells to death.
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